Compare Hims and Hers Health Inc (HIMS) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Lennar Corporation — how do they compare? Hims and Hers Health Inc trades at $28.41 (market cap $6.89B), while Lennar Corporation trades at $77.81 (market cap $18.10B). The key difference: Lennar Corporation is far larger — about 2.6× Hims and Hers Health Inc's market cap, and Lennar Corporation pays a 2.63% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Lennar Corporation for 67 Days on average.
| HIMS | LEN | |
|---|---|---|
Market Cap | $6.89B | $18.10B |
Volume | 5,446,628 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $133.13 |
52-Week Low | $14.52 | $74.44 |
Typical Hold Time | 21 Days | 67 Days |
Enterprise Value | $7.60B | $22.52B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Lennar (LEN) trades at $76.13, down 1.65% on the day, with technical indicators showing bearish momentum. The stock trades below book value (P/B 0.84) and at a discount to peers (P/E 14.42), but faces headwinds from declining revenue and net income margins. Recent news highlights Berkshire Hathaway's growing stake (now 11.2% as of Sept 30, 2026) while Morgan Stanley issued a sell rating, reflecting divergent views on the housing recovery timeline.
The outlook remains challenged by high mortgage rates and weak builder sentiment, though Berkshire's accumulation suggests long-term value. Key risks include the Hunterbrook short report alleging questionable transactions and ongoing margin pressure. With earnings missing estimates for three consecutive quarters and Q3 guidance cut, near-term catalysts appear limited despite attractive valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
